Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01513317 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT01513317 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 76 participants.
The verdict
NCT01513317, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of siltuximab, demonstrated by a reduction in red blood cell (RBC), transfusions to treat the anemia of Myelodysplastic Syndrome (MDS).
Interventions
- DRUG Placebo
- DRUG Siltuximab
- DRUG Best supportive care (BSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01513317
The ClinicalTrials.gov registry entry for NCT01513317 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01513317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01513317 about?
NCT01513317 is a clinical study titled "A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome". The purpose of this study is to evaluate the efficacy of siltuximab, demonstrated by a reduction in red blood cell (RBC), transfusions to treat the anemia of Myelodysplastic Syndrome (MDS).
What is the current status of trial NCT01513317?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2011-11. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01513317?
The interventions under investigation include: Placebo (DRUG), Siltuximab (DRUG), Best supportive care (BSC) (DRUG).
Who is sponsoring clinical trial NCT01513317?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.